A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection

Dr Suresh Kumar Angurana, DM (PICU) Assistant Professor APC, Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh, India

Results:
This systematic review delineates and summarizes clinical features, management, and outcomes of MIS-C associated with SARS-CoV-2 infection. Although most children required intensive care and immunomodulatory therapies, favourable outcomes were reported in the majority with low-mortality rates.

ACADEMIC P.E.A.R.L.S
Pediatric Evidence And Research Learning Snippet

MIS-C: COVID 19 Multisystem Inflammatory syndrome in children
The Pediatric Infectious Disease Journal: September 8, 2020

Case Definition of MIS-C: All 5 Criteria are MUST

1st Criteria : Age : 0-19 years + Fever > 2 days
2nd Criteria : 2 of the 5 systems involvement:
   a. Rash, muco-cutaneous sign, non purulent conjunctivitis
   b. Hypotension or shock
   c. Myocardial dysfunction (pericarditis, coronary changes, elevated troponin I etc)
   d. Coagulopathy (elevated d dimers, prolonged PT/INR)
   e. GI symptoms (diarrhea, vomiting, abdominal pain)
3rd Criteria : Elevated CRP or ESR or Procalcitonin or Ferritin
4th Criteria : No other obvious cause of inflammation / infection
5th Criteria: Evidence of recent COVID 19 infection (RT-PCR+ Or Antibody + Or H/O contact with + patient)

Reference